[1] van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers GJ, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med , 2012, 366(22): 2074-2084.
[2] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer J Clin , 2013, 63(1): 11-30.
[3] Miyawaki Y, Kawachi H, Ooi A, Eishi Y, Kawano T, Inazawa J, Imoto I. Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma. Cancer Sci , 2012, 103(8): 1558-1566.
[4] Kornegoor R, Moelans CB, Verschuur-Maes AHJ, Hogenes MCH, de Bruin PC, Oudejans JJ, Marchionni L, van Diest PJ. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Treat , 2012, 135(1): 49-58.
[5] Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, MacConaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res , 2012, 18(14): 3791-3802.
[6] Xu FP, Xie D, Wen JM, Wu HX, Liu YD, Bi J, Lü ZL, Zeng YX, Guan XY. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett , 2007, 245(1-2): 69-74.
[7] Solyanik GI. Multifactorial nature of tumor drug resistance. Exp Oncol , 2010, 32(3): 181-185.
[8] Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, O'Sullivan MJ, Segura MF, Gallego S, Stallings RL, Bray IM. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer , 2014, doi:
10.1002/ijc.29144.
[9] Ong CA, Shannon NB, Ross-Innes CS, O'Donovan M, Rueda OM, Hu DE, Kettunen MI, Walker CE, Noorani A, Hardwick RH, Caldas C, Brindle K, Fitzgerald RC. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst , 2014, 106(5), doi:
10.1093/jnci/dju050.
[10] Ying JM, Shan L, Li JS, Zhong L, Xue LY, Zhao H, Li LL, Langford C, Guo L, Qiu T, Lu N, Tao Q. Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis. PLoS One , 2012, 7(6): e39797.
[11] Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H, Yasuda T, Shiozaki H, Nishio K. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget , 2014, 5(10): 2962-2973.
[12] Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, Zhang X, Sun YT, Zhan QM, Wu M, Wang MR. Amplification and overexpression of CTTN ( EMS1 ) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res , 2006, 66(24): 11690-11699.
[13] Shi ZZ, Shang L, Jiang YY, Hao JJ, Zhang Y, Zhang TT, Lin DC, Liu SG, Wang BS, Gong T, Zhan QM, Wang MR. Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization. Clin Cancer Res , 2013, 19(21): 5867-5878.
[14] Hu N, Wang CY, Ng D, Clifford R, Yang HH, Tang ZZ, Wang QH, Han XY, Giffen C, Goldstein AM, Taylor PR, Lee MP. Genomic characterization of esophageal squamous cell carcinoma from a High-Risk population in China. Cancer Res ,
